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Abstract 
Background: The Gambia has successfully reduced malaria transmission. The human reservoir of infection could 
further decrease if malaria‑infected individuals could be identified by highly sensitive, field‑based, diagnostic tools 
and then treated.
Methods: A cross‑sectional survey was done at the peak of the 2017 malaria season in 47 Gambian villages. From 
each village, 100 residents were randomly selected for finger‑prick blood samples to detect Plasmodium falciparum 
infections using highly sensitive rapid diagnostic tests (HS‑RDT) and PCR. The sensitivity and specificity of the HS‑
RDT were estimated (assuming PCR as the gold standard) across varying transmission intensities and in different age 
groups. A deterministic, age‑structured, dynamic model of malaria transmission was used to estimate the impact of 
mass testing and treatment (MTAT) with HS‑RDT in four different scenarios of malaria prevalence by PCR: 5, 15, 30, and 
60%, and with seasonal transmission. The impact was compared both to MTAT with conventional RDT and mass drug 
administration (MDA).
Results: Malaria prevalence by HS‑RDT was 15% (570/3798; 95% CI 13.9–16.1). The HS‑RDT sensitivity and specificity 
were 38.4% (191/497, 95% CI 34.2–42.71) and 88.5% (2922/3301; 95% CI 87.4–89.6), respectively. Sensitivity was the 
highest (50.9%, 95% CI 43.3–58.5%) in high prevalence villages (20–50% by PCR). The model predicted that in very 
low transmission areas (≤ 5%), three monthly rounds of MTAT with HS‑RDT, starting towards the end of the dry season 
and testing 65 or 85% of the population for 2 consecutive years, would avert 62 or 78% of malaria cases (over 2 years), 
respectively. The effect of the intervention would be lower in a moderate transmission setting. In all settings, MDA 
would be superior to MTAT with HS‑RDT which would be superior to MTAT with conventional RDT.
Conclusion: The HS‑RDT’s field sensitivity was modest and varied by transmission intensity. In low to very low trans‑
mission areas, three monthly rounds per year of MTAT with HS‑RDT at 85% coverage for 2 consecutive years would 
reduce malaria prevalence to such low levels that additional strategies may achieve elimination. The model prediction 
would need to be confirmed by cluster‑randomized trials.
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Background
After a decade of considerable success in malaria control, 
progress has stalled, with no further reduction of malaria 
cases between 2015 and 2017 [1]. The Gambia is one of 
the sub-Saharan African countries where the number of 
malaria cases has steadily declined due to the scale up 
of malaria control interventions [2, 3]. However, malaria 
transmission has not been interrupted, possibly because 
of the persistence of asymptomatic infections, some of 
them sub-microscopic (sub-patent), that occur in all 
endemic settings [4, 5]. In The Gambia, 60% of infections 
identified during the dry season (January–June) and 30% 
of those during the transmission season (July–December) 
were asymptomatic, with a third of these sub-patent [6]. 
As transmission declines, the proportion of sub-patent 
infections among infected and asymptomatic individuals 
may increase, although their contribution to transmis-
sion remains unclear [4, 7].
Strategies such as mass drug administration (MDA) or 
mass testing and treatment (MTAT) target the human 
reservoir of infection and may decrease malaria preva-
lence to such low levels that other strategies may achieve 
elimination. While MDA aims at administering a full 
anti-malarial treatment to the whole population, without 
screening for either symptoms or infections [8], MTAT 
would treat only positive individuals identified through 
mass testing, regardless of symptoms [9]. The low sen-
sitivity of conventional rapid diagnostic tests (RDTs), its 
detection limit is approximately 100–200 parasites/µl 
and comparable to light microscopy [5, 10–13], remains 
a major challenge for the success of MTAT campaigns. In 
Burkina Faso, Ethiopia and Kenya, MTAT did not achieve 
significant or sustained reductions in malaria transmis-
sion in communities [14, 15] and school children [16, 17], 
partly because conventional RDTs would not detect low-
density, sub-patent infections [18, 19].
Low-density infections can be identified by more sen-
sitive molecular diagnostic methods that detect the 
parasites’ nucleic acid. Depending on the blood volume 
examined and the molecular target, molecular tests can 
detect infections with parasite densities as low as 0.02–
0.1 parasites/µl [20]. However, this approach is complex, 
expensive, and not easily field deployable as it requires 
skilled staff and a central laboratory [18, 21].
The highly sensitive RDTs (HS-RDT) were developed 
for the field detection of low-density infections, with a 
detection limit of 40–125 pg/ml histidine-rich protein-2 
(HRP2), tenfold lower than that of conventional SD Bio-
line Malaria Ag P.f RDT (800–1000  pg/ml) [11]. When 
compared to quantitative reverse-transcription PCR (q)
RT-PCR, HS-RDT’s sensitivity was 44% in asympto-
matic individuals in Myanmar (low transmission), 47% 
in malaria naïve individuals infected experimentally with 
blood stage Plasmodium falciparum parasites, and 84% 
in Ugandan asymptomatic children (high transmission); 
its specificity was greater than 96% [22]. In Myanmar, 
under laboratory conditions, HS-RDT’s sensitivity was 
51% compared to the combined high-volume ultrasensi-
tive qPCR and Quansys human malaria 4-plex enzyme-
linked immunosorbent assay (ELISA) tests, and 54% 
when compared to only ultrasensitive qPCR. In the field, 
the HS-RDT sensitivity was 36% compared to ultra-sen-
sitive qPCR; HS-RDTs had a twofold higher sensitivity 
than conventional RDTs and microscopy [18]. In Papua 
New Guinea, HS-RDT detected 51% of the P. falciparum 
infections detected by ultra-sensitive qPCR and 26% of P. 
falciparum infections detected by both standard qPCR 
and ultra-sensitive qPCR [19].
It is unclear what effect MTAT with HS-RDT would 
have on malaria transmission as a proportion of infected 
people would remain undetected and untreated. The 
objective of this study was to determine the field sensi-
tivity and specificity of HS-RDT (reference test: var gene 
acidic terminal sequence  (varATS) PCR. These values 
were used to predict the effect of MTAT campaigns with 
HS-RDT on malaria prevalence using a mathematical 
model.
Methods
Study design and participants
Malaria transmission in The Gambia is highly seasonal, 
with peak transmission from October to November. A 
cross-sectional survey was conducted over a month (7 
November to 8 December 2017) in 47 villages in eastern 
Gambia. The selected villages with populations between 
100 and 800 residents are included as part of the Health 
and Demographic Surveillance System (HDSS) (Fig. 1). In 
each village, individuals aged at least 6 months were ran-
domly selected for the survey; in smaller villages, all the 
inhabitants were selected.
Individual finger-prick blood samples were collected 
for HS-RDT and diagnostic PCR, for the latter on fil-
ter paper to diagnose malaria infections. Selected par-
ticipants underwent medical examination and axillary 
temperature was measured by a digital thermometer. 
Participants with a positive HS-RDT and fever (axillary 
temperature ≥ 37.5 °C) and/or history of fever in the pre-
vious 24  h were treated with artemether-lumefantrine, 
the first line treatment in The Gambia.
Data management
Data was collected and managed using the REDCap 
(Research Electronic Data Capture) data capture tool that 
has an intuitive interface for validated data entry, audit 
trails for tracking and exporting data. Individual data 
were completed for demographic characteristics, history 
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of fever and recent anti-malarial use, axillary tempera-
ture, long-lasting insecticidal net (LLIN) ownership and 
use, and prior indoor residual spraying (IRS).
Sample size
Assuming malaria prevalence of 10%, 100 individuals per 
village would be able to estimate malaria prevalence with 
a precision of ± 6%.
Malaria detection and laboratory analysis
The HS-RDT was carried out following the manufac-
turer’s recommendations. Briefly, a finger-prick blood 
sample was collected and delivered to the sample well in 
the test cassette. Four drops of buffer were added and the 
results were interpreted within 20 min by a study nurse 
[11].
The varATS assay was used to generate qualitative 
P. falciparum results. Briefly, three 3-mm dried blood 
spots were punched into 96-well plates and digested 
in 20  µl of proteinase K and 180  µl of ATL tissue lysis 
buffer solution. The Plasmodium DNA was extracted 
using the QIAamp 96 DNA QIAcube HT kit (Qiagen, 
Germany) and Qiacube  HT® robot. Extracted DNA was 
eluted into 80 µl of elution buffer and stored at − 20 °C 
till further use. For the analysis, the var gene acidic ter-
minal sequence (varATS, 59 copies/genome) of P. falci-
parum was amplified [23]. All PCR reactions included 
10 standards prepared from tenfold serially diluted sam-
ples containing known numbers of infected erythrocytes 
diluted in whole blood. The limit of detection of the PCR 
assay is approximately 0.2 parasites/µl of blood [23]. The 
PCR output was analysed using the BioRad CFX Man-
ager software.
Statistical analysis
Malaria prevalence was calculated by dividing the num-
ber of positive samples, either by HS-RDT or PCR, by 
the total number of tested samples. An asymptomatic 
infection was defined as an individual with positive 
HS-RDT or PCR without history of fever in the previ-
ous 24  h and axillary temperature ≤ 37.5  °C [24] at the 
time of blood collection. PCR was the reference test to 
estimate the diagnostic accuracy of HS-RDT. The sensi-
tivity was estimated as follows: true positives/(true posi-
tives + false negatives); specificity as true negatives/(true 
negatives + false positives); positive predictive value as 
true positives/(true positive + false positives); negative 
predictive value as true negatives/(true negatives + false 
negatives). The Pearson’s Chi squared test was used to 
compare the HS-RDT’s sensitivity and specificity by age 
and transmission intensity. Univariate and multivari-
ate logistic regression analysis was used to determine 
the odds of being “false negative” by age and the odds 
of being “false positive” by intensity of transmission. 
Fig. 1 Study sites in upper river region‑south bank and Plasmodium falciparum infection prevalence by PCR. Filled light blue circle: very low 
prevalence (< 5%), filled dark blue circle: low‑moderate transmission (5 to < 20%), filled red circle: high prevalence (20–50%)
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The regression models were adjusted for gender, IRS 
in the last 6 months and use of LLINs at night. Malaria 
prevalence by PCR was used as a proxy of transmission 
intensity, categorized as very low (< 5%,) low-moderate 
(5 to  < 20%) and high (20–50%) transmission. The asso-
ciation between the HS-RDT sensitivity and transmis-
sion intensity was determined by fitting a line between 
the two quantities derived from a log-odds regression 
model [4] implemented within a Bayesian based frame-
work. This framework was implemented in the statistical 
software package JAGS, and parameter inference based 
on Markov Chain Monte Carlo simulations using the R 
package rjags version 4-8 (https ://CRAN.R-proje ct.org/
packa ge=rjags ). Infection status was defined by four cat-
egories: (1) malaria-infected individuals with detectable 
HRP2 levels: both PCR and HS-RDT positives; (2) indi-
viduals with a recently cleared infection, either naturally 
or by treatment, with residual HRP2: PCR negative and 
HS-RDT positive; (3) malaria-infected individuals with-
out residual HPR2: PCR positive and HS-RDT negative 
test result; and, (4) non-infected individuals: both nega-
tive PCR and HS-RDT. The map of the study sites was 
generated using Quantum (Q)GIS version 7.5.0 with 
GRASS 7.4.4 programs. The administrative base map of 
The Gambia was created by downloading the “shapefiles” 
of The Gambia into QGIS and the administrative layers 
were generated. A final “shapefile” was created using the 
village coordinates and PCR infection prevalence and 
then layered onto the administrative map of The Gambia.
Mathematical modelling
An existing deterministic age-structured dynamic 
model of malaria transmission was used to estimate the 
impact of MTAT with HS-RDT (compared to no inter-
vention) on malaria prevalence and the proportion of 
clinical malaria cases averted [25]. The model assumes 
newborns start as susceptible with some maternally 
acquired immunity, which decays within 6 months. After 
an infectious mosquito bite, individuals have a probabil-
ity of developing symptomatic or asymptomatic malaria. 
The probability of becoming infected after an infectious 
bite depends on the individual’s level of pre-erythrocytic 
immunity, and the probability of developing sympto-
matic or asymptomatic infection depends on their level 
of blood-stage immunity. The acquisition of both types of 
immunity depends on population-level of exposure. Indi-
viduals developing symptomatic malaria have a probabil-
ity of being treated and then prophylactically protected. 
Untreated individuals with symptomatic infection are 
assumed to progress to asymptomatic infection after an 
average of 5 days. Asymptomatic individuals are assumed 
to remain P. falciparum infected for 310 days on average 
[26]. Infections are defined as either patent (detected by 
microscopy) or sub-patent (detected only by molecular 
method). Unless prophylactically protected by an anti-
malarial drug, individuals can be re-infected or super-
infected at any time.
The model was extended to include MTAT with HS-
RDTs compared to either MTAT with conventional RDTs 
or MDA implemented as three monthly rounds per year 
for 2 consecutive years. The MTAT is implemented in 
the model whereby, at defined time points, a proportion 
of individuals (the intervention coverage) are tested. A 
proportion of infected individuals are assumed to test 
positive (determined by the diagnostic test’s sensitivity), 
treated and moved to the ‘prophylactic protection’ com-
partment. It is assumed that there is non-random cov-
erage of who partakes in each intervention round: the 
population is split in two groups, one which partakes in 
all three treatment rounds, and one which has random 
and uncorrelated coverage over the three rounds.
The HS-RDT’s specificity is accounted for by assuming 
that a proportion of uninfected individuals will be HS-
RDT positive and will receive treatment and prophylactic 
protection. MDA is implemented in the model by assum-
ing that at defined time points, a proportion (equal to the 
MDA coverage) of individuals are treated (regardless of 
infection status) and move to the ‘prophylactic protec-
tion’ compartment. Coverage between treatment rounds 
is assumed to be correlated as described above.
The model used the HS-RDT sensitivity and specificity 
values estimated by the survey. It was assumed that sen-
sitivity of conventional RDT is 22% lower than the HS-
RDT and has 95% specificity [22]. The model assumed 
recently treated individuals remain RDT or HS-RDT 
positive for 15  days [27] and 30  days [28], respectively. 
The probability of detection during this period is equal 
to the sensitivity of each test in asymptomatic indi-
viduals. In the simulations, dihydroartemisinin–pipe-
raquine (DHA–PQ) was used for MTAT and MDA with 
the post-treatment prophylactic period assumed to be 
30  days on average. Finally, seven scenarios are simu-
lated: (i) no mass intervention; (ii) MTAT with conven-
tional RDT at 65%; (iii) 85% coverage; (iv) MTAT with 
HS-RDT at 65% coverage; (v) 85% coverage; (vi) MDA at 
65% coverage, and (vii) 85% coverage. All interventions 
are implemented by three monthly round per year for 2 
consecutive years, starting at the end of the dry season. 
All simulations are run according to different transmis-
sion intensity as determined by PCR-determined malaria 
prevalence namely; very low (5%), low (15%), moderate 
(30%), and high (60%).
Consent
Community verbal approval was followed by individual 
written consent for adults who also provided consent for 
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children below 18 years of age. Children between 12 and 
17 years provided assent. Ethical approval was obtained 
from the Gambia Government/Medical Research Coun-
cil Joint Ethics Committee.
Results
A total of 4060 participants distributed in 47 villages 
were screened (Fig. 1); the median age was 13 years (IQR: 
6, 31); 55.7% (2258/4054) of study participants were 
female and coverage of control interventions (LLIN and 
IRS) was high (Table 1).
The prevalence of P. falciparum infection was 15.0% 
(570/3798; 95% CI 13.9–16.1) by HS-RDT and 13.1% 
(497/3798; 95% CI 12.0–14.2) by PCR. HS-RDT’s sen-
sitivity and specificity were 38.4% (191/497; 95% CI 
34.2–42.7) and 88.5% (2922/3301; 95% CI 87.4–89.6), 
respectively (Table 2).
Among individuals with fever (temperature ≥ 37.5  °C) 
or history of fever, malaria prevalence by HS-RDT 
was 17.1% (200/1172; 95% CI 14.9–19.2) and 14.1% 
(369/2610; 95% CI 12.8–15.5) in those without fever. HS-
RDT sensitivity was similar in individuals with (41.5%, 
63/152; 95% CI 33.6–49.3%) or without (37.3%, 128/343; 
95% CI 32.2–42.4) fever or history of fever in the previ-
ous 24 h (p = 0.38).
The HS-RDT sensitivity increased with increasing 
P. falciparum prevalence by PCR (Fig.  2), and was the 
highest, 50.9% (85/167; 95% CI 43.3–58.5) in high trans-
mission villages (20–50% prevalence) (Fig.  3). The HS-
RDT sensitivity was significantly lower and specificity 
higher in villages with low-moderate prevalence than in 
those with high prevalence (p < 0.01) (Additional file  1: 
Table S1).
The HS-RDT specificity was significantly lower in 
high 76.1% (229/301, 95% CI 71.3–80.9) than in low-
moderate transmission 89.3% (1916/2146, 95% CI 87.9–
90.6) (χ2 = 42.5, p < 0.01) or very low transmission 90.9% 
(777/854, 95% CI 89.1–92.9) (χ2 = 43.9, p < 0.01) villages 
(Table 3). Additional file 1: Table S1 shows the compari-
son of the HS-RDT sensitivity and specificity by intensity 
of transmission.
More than half of PCR positive samples were negative 
by HS-RDT (306/497; 61.6%, 95% CI 57.3–65.8), with the 
largest proportion of ‘false negatives’ in villages with low-
moderate transmission. The odds of being false negative 
in the low-moderate and high prevalence villages was not 
different than in the very low prevalence villages. (Addi-
tional file 2: Table S2, Fig. 4).
The HS-RDT sensitivity did not differ between older 
children and adults but was significantly lower in chil-
dren below 5  years than in older children and adults 
(Table 4, Fig. 5). The older children and adults had about 
70% lower odds of being false negative, i.e., PCR positive 
and HS-RDT negative, than younger children (Table 5).
Table 1 Participants demographic characteristics
Variable N (%)
Age group (N = 4024)
 0 to < 5 667 (16.6)
 5 to < 10 871 (21.7)
 10 to < 20 996 (24.8)
 20 to < 40 827 (20.6)
 40 to < 90 663 (16.5)
Gender (N = 4054)
 Female 2258 (55.7)
 Male 1796 (44.3)
Reported LLIN ownership (N = 3998)
 Yes 3799 (95.0)
Used LLIN the previous night (N = 4009)
 Yes 3512 (87.6)
Sprayed IRS in the previous 6 months (N = 3992)
 Yes 3642 (91.2)
Table 2 Performance of highly sensitive rapid diagnostic tests as compared to PCR
PCR HS-RDT Total
HS-RDT positive HS-RDT negative
Positive 191 306 497
Negative 379 2292 3301
Total 570 3228 3798
Value (%) 95% CI
Prevalence by HS‑RDT 15.0 13.9–16.1
Sensitivity 38.4 34.2–42.7
Specificity 88.5 87.4–89.6
Positive predictive value 33.5 29.6–37.4
Negative predictive value 90.5 89.5–91.5
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Overall, 11.5% (379/3301) individuals were ‘false posi-
tives’, i.e. HS-RDT positive and PCR negative. This pro-
portion increased with increasing malaria prevalence by 
PCR with the odds of being false positive significantly 
higher in the high transmission villages than in very low 
transmission villages (Additional file 3: Table S3, Fig. 4). 
Only 3.7% (11/299; 95% CI 1.6–5.8) false positive partici-
pants reported taking an anti-malarial treatment within 
the previous month, with similar proportions in low-
moderate (4.8%, 8/78) and high (4.2%, 3/72) transmission 
villages.
For the malaria transmission model, the HS-RDT sen-
sitivity is assumed to be 38.4%. The proportion of false 
positives (PCR negative and HS-RDT positive) was 
assumed to be 10%. At very low prevalence (~ 5%), three 
monthly rounds of MTAT with HS-RDT per year at 85% 
coverage would decrease prevalence by 80%, from 5 to 
around 1%, up to 18 months after the final MTAT round 
(solid red line, Fig. 6a). In addition, 78.4% of clinical cases 
would be averted at the end of the 2 years. At 65% cover-
age malaria prevalence would decrease to 2% in 2 years 
averting 62.0% of malaria cases but it would return to 
pre-MTAT levels 12 months after the last monthly round 
of MTAT. The impact of MTAT with conventional RDT 
would be lower; at 85 and 65% coverage, it would avert 
66.5 and 51.8% of cases, respectively. The effect of the 
intervention would be more marked for MDA as 93 and 
80.5% of cases would be averted at 85 and 65% coverage, 
respectively (Additional file 4: Table S4 and Fig. 6a).
At low prevalence (~ 15%), three monthly rounds of 
MTAT with HS-RDT at 85% coverage would decrease 
prevalence to around 7 and 5% in the first and second 
Fig. 2 Association between the highly sensitive rapid diagnostic 
test sensitivity and Plasmodium falciparum infection prevalence 
by PCR. Filled pink circle: each pink dot represents a village and 
the grey horizontal and vertical lines are 95% confidence intervals 
associated with the prevalence and sensitivity estimates, blue solid 
line: the fitted relationship between the two quantities derived from 
a log‑odds regression model between PCR and HS‑RDT prevalence 
implemented within a Bayesian framework. Full details of model 
structure have been previously published [25]
Fig. 3 Performance of highly sensitive rapid diagnostic test by transmission intensity
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year, respectively. Prevalence would return to almost 
pre-MTAT levels 12  months after the last round if the 
intervention is not continued (solid red line, Fig.  6b); 
the intervention would avert 66.8% of malaria cases 
over 2  years (Additional file  4: Table  S4). MDA at 85% 
coverage would decrease malaria prevalence from 12 to 
about 5% in the first year and 3% in the second year that 
would increase only after 18 months.
In moderate (prevalence ~ 30%) and high (preva-
lence ~ 60%) transmission areas, MTAT with HS-RDT 
Table 3 Performance of the highly sensitive rapid diagnostic test by malaria prevalence
Very low transmission 
(prevalence < 5%)
Low-moderate transmission 
(prevalence 5 to < 20%)
High transmission (prevalence 
20–50%)
HS-RDT HS-RDT HS-RDT
Positive Negative Total Positive Negative Total Positive Negative Total
PCR positive 14 18 32 92 206 298 85 82 167
PCR negative 77 777 854 230 1916 2146 72 229 301
 Total 91 795 886 322 2122 2444 157 311 468
PCR prevalence 3.6 (2.5–5.1) 12.2 (10.9–13.5) 35.7 (31.3–40.2)
Sensitivity (95% CI) 43.8 (26.4–62.3) 30.9 (25.6–36.1) 50.9 (43.3–58.5)
Specificity (95% CI) 90.9 (89.1–92.9) 89.3 (87.9–90.6) 76.1 (71.3–80.9)
Positive predictive value (95% CI) 15.4 (8.7–24.5) 28.6 (23.6–33.5) 54.1 (46.4–61.9)
Negative predictive value (95% CI) 97.7 (96.4–98.7) 90.3 (89.0–91.6) 73.6 (68.7–78.5)
Fig. 4 Prevalence of Plasmodium falciparum infections as determined by highly sensitive rapid diagnostic test and PCR by village. Dark blue bar: 
proportions of PCR positive HS‑RDT positive infections, dark yellow bar: proportions of PCR negative HS‑RDT positive infections, light blue bar: 
proportion of PCR positive HS‑RDT negative infections, grey bar: proportions of PCR negative HS‑RDT negative infections
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at 85% coverage would decrease malaria prevalence by 
about 60% during the intervention months; however, 
prevalence would rapidly return to pre-MTAT levels after 
the last round, i.e. 6 months in moderate and 3 months 
in high transmission areas (Fig. 6c, d). In moderate trans-
mission settings, MTAT with a HS-RDT over 2  years 
would avert 53 and 40% of malaria cases at 85 and 65% 
coverage, respectively (Additional file  4: Table  S4). The 
percentage of cases averted is lower for MTAT with a 
conventional RDT (42.8 and 33.4% at 85 and 65% cover-
age, respectively) and higher for MDA (80.6 and 61.9% 
at 85 and 65% coverage, respectively). In all transmission 
settings, 85% coverage of MTAT with a HS-RDT had 
similar impact as MDA with a coverage of 65%.
Discussion
HS-RDT sensitivity was low, missing 62% of infected 
individuals identified by PCR, but was similar to that 
reported from Myanmar (36.6%) [18], Papua New Guinea 
(51%) [19] and Ethiopia (33.9%) [29], confirming the poor 
performance of this diagnostic test in detecting low-den-
sity malaria infections. Despite this, malaria prevalence 
Table 4 Performance of highly sensitive rapid diagnostic test by age
≤5 years 5 to < 10 years 10 to < 18 years 18 to < 40 years 40–90 years
%, n/N
(95% CI)
%, n/N
(95% CI)
%, n/N
(95% CI)
%, n/N
(95% CI)
%, n/N
(95% CI)
PCR prevalence 10.7%, 67/626
(8.3–13.1)
12.7%, 105/824
(10.5–15.2)
14.5%, 119/823
(12.1–16.9)
13.8%, 121/874
(11.6–16.1)
13.1, 81/619
(10.4–15.7)
Sensitivity 17.9%, 12/67
(8.7–27.1)
43.8%, 46/105
(34.3–53.3)
43.7%, 52/119
(34.8–52.6)
40.5%, 49/121
(31.7–49.2)
39.5%, 32/81
(28.9–50.2)
Specificity 93.0%, 520/5599
(90–95.1)
87.1%, 626/719
(84.6–89.5)
84.5%, 597/704
(81.8–87.6)
87.9%, 662/753
(85.6–90.3)
91.8%, 494/538
(89.5–94.1)
Positive predictive value 23.5%, 12/51
(11.9–35.2)
33.1%, 46/139
(25.3–40.9)
32.7%, 52/159
(25.4–39.9)
35.0%, 49/140
(27.1–42.9)
42.1%, 32/76
(31.0–53.2)
Negative predictive value 90.4%, 520/575
(88.03–92.8)
91.4%, 626/685
(89.3–93.4)
89.9%, 597/664
(87.6–92.2)
90.2%, 662/734 (88.03–92.3) 90.9%, 494/543
(88.6–93.4)
Comparison of HS‑RDT sensitivity of older 
children and adults to children < 5 years
1 χ2 = 12.3, p < 0.01 χ2 = 12.6, p < 0.01 χ2 = 10, p < 0.01 χ2 = 8.2, p < 0.01
Fig. 5 Performance of highly sensitive rapid diagnostic test by age. a Dark blue bar: percentage of population that are PCR positive HS‑RDT positive, 
dark yellow bar: percentage of population that are PCR negative HS‑RDT positive, light blue bar: percentage of population that are PCR positive 
HS‑RDT negative, grey bar: percentage of population that are PCR negative HS‑RDT negative. b Solid blue line: sensitivity of HS‑RDT (compared to 
PCR) for different age groups, with 95% confidence intervals, solid red line: percentage of the population that are PCR negative and HS‑RDT positive 
for different age groups, with 95% confidence intervals
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estimated by HS-RDT was similar, even slightly higher, to 
that determined by PCR, a result partly due to the high 
proportion of false positives, i.e., samples positive by HS-
RDT and negative by PCR. The latter could be explained 
by residual circulating malaria antigen (HRP2) lasting up 
to 28 days after infection clearance [28, 30], from either 
anti-malarial treatment [31] or by the immune system 
[32]. However, some individuals may have been infected 
with low parasite density fluctuating below the detec-
tion threshold of PCR [32–34]. This could be investigated 
using a larger volume of blood for the molecular analy-
sis [19]. In these individuals with low-density infections, 
parasite density may increase and are detectable by RDTs 
or microscopy [35].
Most discrepant results were represented by false nega-
tives, i.e., negative by HS-RDT and positive by PCR, 
possibly due to the lower detection threshold of PCR 
compared to HS-RDT [23]. False negative individuals 
may harbour low-density infections but they may still be 
infectious to the vector or may progress towards clinical 
disease [33, 35]. In addition, a false negative result could 
be due to the deletion of the HRP2 gene [36], HRP2 anti-
gens [11] although this maybe unlikely in this setting. As 
P. falciparum density was not measured, it is not pos-
sible to determine whether false negative samples had 
parasite densities below the HS-RDT detection thresh-
old. Such limitation also prevents to establish whether 
the differential performance of the HS-RDT by age 
group and prevalence could be explained by variations 
in parasite densities. Indeed, HS-RDT’s sensitivity and 
specificity varied by malaria prevalence, with the highest 
sensitivity and the lowest specificity in high transmission 
villages. This may be due to the higher probability of 
being infected (and re-infected) at any given moment 
(high sensitivity), possibly with higher parasite densities 
in individuals repeatedly infected, and by the detection of 
circulating P. falciparum HRP2 antigens from past infec-
tions (low specificity). Where malaria prevalence was 
very low, despite missing more than half of infected indi-
viduals, HS-RDT would identify those with circulating 
parasite antigens who had been infected about 1 month 
earlier [37, 38], indicating areas of ongoing transmission.
In this context, treating HS-RDT positive individuals, 
either with a detectable infection by PCR or with cir-
culating HRP2 from a previous infection, could further 
decrease malaria prevalence, when using a treatment 
with a long post-treatment prophylactic period such as 
dihydroartemisinin–piperaquine (DHA–PQ) [39]. When 
malaria transmission significantly decreases, it becomes 
heterogenous and focal, with higher transmission in a 
few compounds or households and lower transmission 
in surrounding households [40]. In this context, infected 
individuals or with evidence of a previous infection may 
indicate areas of ongoing transmission. This is plausible 
in The Gambia where households with a malaria-infected 
individual at the beginning of the transmission season 
were more likely to have one household member acquire 
clinical malaria [6].
Trials evaluating the effect of multiple MTAT using 
conventional RDTs found temporary reductions of 
malaria prevalence in communities in Burkina Faso 
and Zambia [14, 41], and in schools in Kenya [16]. Such 
transient effect is probably due to the inability of con-
ventional RDTs to identify and treat individuals with 
Table 5 Risk of being false negative: PCR positive and HS-RDT negative by age, LLIN use and gender
HS-RDT false negatives 
n/N, (%)
OR (95% CI) p value AOR (95% CI) p value
Age (years)
 ≤ 5 55/67 (82.1) 1 1
 5 to < 10 59/105 (56.2) 0.28 (0.13–0.58) < 0.01 0.28 (0.13–0.6) < 0.01
 10 to < 18 67/119 (56.3) 0.28 (0.14–0.6) < 0.01 0.29 (0.14–0.6) < 0.01
 18 to < 40 72/121 (59.5) 0.32 (0.16–0.66) < 0.01 0.32 (0.16–0.7) < 0.01
 40 to < 90 49/81 (60.5) 0.33 (0.16–0.7) < 0.01 0.33 (0.15–0.7) < 0.01
IRS
 No 1
 Yes 0.52 (0.3–1.03) 0.06 0.50 (0.3–1.0) 0.05
LLIN at night
 No 1
 Yes 0.89 (0.5–1.6) 0.69
Gender
 Male 1
 Female 0.89 (0.6–1.3) 0.53
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low-density infections. In addition, according to a pub-
lished mathematical model, MTAT with sensitive tests 
would increase the probability of local malaria elimi-
nation only in very low transmission settings [42]. The 
mathematical model presented in this paper compared 
MDA and MTAT with either conventional RDT or HS-
RDT. In all transmission scenarios, MDA would be 
more efficacious than MTAT in reducing malaria prev-
alence, although such effect would be transient in areas 
of intense transmission.
Nevertheless, at very low or low transmission intensi-
ties, MTAT with HS-RDT at 85% coverage would have 
a similar effect than MDA at 65% coverage and reduce 
malaria prevalence by 80%, from 5 to 1% for about 
18  months after the last MTAT round. At lower cov-
erage, MTAT with HS-RDT would have a much lower 
effect, like that obtained by MTAT with conventional 
RDT at 85% coverage. The success of MDA depends 
on high coverage which in turn is heavily influenced 
by its acceptability by the local populations, which 
can change and decrease over time. MTAT may be 
more acceptable to the local population as it identifies 
and treats infected individuals [43, 44]. An additional 
advantage would be to reduce the risk of treatment-
related adverse events as only HS-RDT positive indi-
viduals, in this context a small percentage of the whole 
population, would be treated. Moreover, MTAT with 
a HS-RDT may be an alternative to MDA is areas of 
Fig. 6 Mathematical model simulation of the predicted impact of the interventions (MTAT with HS‑RDT, MTAT with conventional RDT, and MDA) 
implemented for three monthly rounds for 2 consecutive years on PCR prevalence. The intervention is implemented in a seasonal transmission 
setting with four levels of transmission intensity. The orange arrows indicate the timing of each MTAT/MDA round. Solid grey line: no MTAT, dashed 
light blue line: co‑RDT MTAT, 65% coverage, solid light blue line: co‑RDT MTAT, 85% coverage, dashed red line: HS‑RDT MTAT, 65% coverage, solid red 
line: HS‑RDT MTAT, 85% coverage, dashed dark blue line: MDA, 65% coverage, dashed solid dark blue line: MDA, 85% coverage
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multi-drug resistance [45] as it would reduce the drug 
pressure and thus the selection of resistant parasites.
The timing of MTAT implementation may also be 
important; in a highly seasonal setting, the three rounds 
should be implemented at the end the dry season, 
before the malaria seasonal transmission starts. This 
may improve the HS-RDT performance as individuals 
infected during the previous transmission season would 
have cleared any residual parasite-circulating antigen, 
thus reducing the percentage of false positives.
The mathematical model used to estimate the effect 
on MTAT with HS-RDT is based on several assump-
tions. These predictions would need to be empirically 
confirmed by field studies, e.g., cluster randomized trials, 
which may compare MDA against MTAT or, depending 
on the malaria prevalence, the two interventions imple-
mented sequentially, i.e., MDA to reduce malaria preva-
lence to levels at which MTAT could have an additional 
effect.
Conclusions
HS-RDTs were developed with the aim of reducing the 
human reservoir of infection as they would identify 
asymptomatic, malaria-infected individuals [46] to be 
treated with an artemisinin-based combination treat-
ment. Despite the sub-optimal sensitivity and specificity, 
HS-RDT could be used to identify groups of individuals 
at higher risk of infection. The mathematical model pre-
dicts that in low to very low transmission areas, MTAT 
with HS-RDT would substantially decrease malaria prev-
alence. Such prediction would need to be confirmed by 
cluster-randomized trials.
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